Risk factors for emotional and relationship problems in peyronie's disease

Journal of Sexual Medicine

Volumn 5, Issue 9, 2008, Pages 2179-2184

  Smith, James F ^a   Walsh, Thomas J ^a   Conti, Simon L ^a   Turek, Paul ^a   Lue, Tom ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cross Sectional Analysis; Epidemiology; Erectile Dysfunction; Psychosocial; Quality of Life; Risk Factors

Indexed keywords

ADULT; AGED; ANAMNESIS; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; EMOTIONAL DISORDER; HUMAN; HUMAN RELATION; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PENIS ERECTION; PEYRONIE DISEASE; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; PSYCHOSOCIAL DISORDER; QUALITY OF LIFE; RISK FACTOR; SEXUAL INTERCOURSE;

EID: 51349096620     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2008.00949.x     Document Type: Article

References (23)

1. Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991;146:1007.
2. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie's disease: Results of a large survey. BJU Int 2001;88:727.
3. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, Davis R, Hellstrom W. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 2004;171:2350.
4. Rhoden EL, Teloken C, Ting HY, Lucas ML, Teodosio da Ros C, Ary Vargas Souto C. Prevalence of Peyronie's disease in men over 50-y-old from Southern Brazil. Int J Impot Res 2001;13:291.
5. Kadioglu A, Akman T, Sanli O, Gurkan L, Cakan M, Celtik M. Surgical treatment of Peyronie's disease: A critical analysis. Eur Urol 2006;50:235.
6. Cavallini G, Modenini F, Vitali G. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease. Urology 2007;69:950.
7. Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: A randomized and prospective study. Urology 2006;67:1038.
8. Riedl CR, Sternig P, Galle G, Langmann F, Vcelar B, Vorauer K, Wagner A, Katinger H, Pfluger H. Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: A randomized placebo-controlled double-blind prospective clinical study. Eur Urol 2005;48:656.
9. Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: A prospective, placebo-controlled, randomized study. Eur Urol 2005;47:530.
10. Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: A randomized double-blind, placebo-controlled study. Int J Impot Res 2004;16:238.
11. Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Giurioli A, Jannini EA, Vespasiani G. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol 2004;171:1605.
12. Delanian S, Porcher R, Balla-Mekias S, Lefaix JL. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol 2003;21:2545.
13. Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: A double-blind, placebo-controlled, randomized study. J Urol 2007;178:1398.
14. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990;144:1376.
15. Rosen R, Henne J, Catania J, Althof S. Patient-reported psychosocial impact of Peyronie's disease. J Sex Med 2008;5(suppl1):39.
16. Bella AJ, Perelman MA, Brant WO, Lue TF. Peyronie's disease (CME). J Sex Med 2007;4:1527.
17. Broderick GA, Donatucci CF, Hatzichristou D, Torres LO, Valiquette L, Zhao Y, Loughney K, Sides GD, Ahuja S. Efficacy of tadalafil in men with erectile dysfunction naive to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate. J Sex Med 2006;3:668.
18. Dean J, Hackett GI, Gentile V, Pirozzi-Farina F, Rosen RC, Zhao Y, Warner MR, Beardsworth A. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: Results of a multicenter, randomized, open-label, crossover study. J Sex Med 2006;3:650.
19. King R, Juenemann KP, Levinson IP, Stecher VJ, Creanga DL. Correlations between increased erection hardness and improvements in emotional well-being and satisfaction outcomes in men treated with sildenafil citrate for erectile dysfunction. Int J Impot Res 2007;19:398.
20. Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int 2002;89:895.
21. Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, Mulhall J, Perovic S, Ralph D, Stackl W. Peyronie's disease. J Sex Med 2004;1:110.
22. Koren H, Alth G, Schenk GM, Jindra RH. Induratio penis plastica: Effectivity of low-dose radiotherapy at different clinical stages. Urol Res 1996;24:245.
23. Hellstrom WJ, Bivalacqua TJ. Peyronie's disease: Etiology, medical, and surgical therapy. J Androl 2000;21:347.